Early 'in-lab' use of levosimendan in patients with cardiogenic shock unsuitable for intra-aortic balloon pump counterpulsation.
Intra-aortic balloon pump counterpulsation is currently the most used mechanical assistance device for patients with cardiogenic shock due to acute myocardial infarction. However, a recently published meta-analysis and trial failed to confirm previous knowledge. We report the results of four patients with ST elevation myocardial infarction, complicated by cardiogenic shock unsuitable for intra-aortic balloon pump counterpulsation treated with early levosimendan infusion during primary percutaneous coronary intervention.
Interventional Cardiology, Policlinico Casilino, Via Casilina 1049, 00169 Rome, Italy.
Francesco
F
Summaria
Marina
M
Mustilli
Antonella
A
Sette
Chiara
C
Lanzillo
Enrico
E
Romagnoli
D000368:Aged; D002316:Cardiotonic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D015908:Counterpulsation; D006801:Humans; D006835:Hydrazones / Q000008:administration & dosage / Q000627:therapeutic use*; D007262:Infusions, Intravenous; D007423:Intra-Aortic Balloon Pumping; D009203:Myocardial Infarction / Q000150:complications / Q000628:therapy*; D062645:Percutaneous Coronary Intervention / Q000379:methods*; D011724:Pyridazines / Q000008:administration & dosage / Q000627:therapeutic use*; D012770:Shock, Cardiogenic / Q000209:etiology / Q000628:therapy*; D000077464:Simendan; D013997:Time Factors; D016896:Treatment Outcome
D002316:Cardiotonic Agents; D006835:Hydrazones; D011724:Pyridazines; D000077464:Simendan
cardiogenic shock; intra-aortic balloon pump counterpulsation; levosimendan; primary PCI; transradial approach